Mirum Pharmaceuticals, Inc. (MIRM)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 24.49 |
| Open | 24.43 |
| Bid | 24.39 x 400 |
| Ask | 24.48 x 200 |
| Day's range | 24.17 - 24.78 |
| 52-week range | 23.14 - 35.56 |
| Volume | |
| Avg. volume | 500,854 |
| Market cap | 1.153B |
| Beta (5Y monthly) | 1.14 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.00 |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 48.91 |
ZacksMirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Mirum Pharmaceuticals (MIRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., April 11, 2024--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business WireMirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
FOSTER CITY, Calif., April 02, 2024--Mirum's LIVMARLI Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
© 2024 Yahoo. All rights reserved.